Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Granzyme K and Cardiac Allograft Vasculopathy: A novel therapeutic target
FY 2016-17
Summary
Chronic rejection is the number one cause of death in heart transplant patients after one year. An inflammatory protein measured in the bloodstream of transplant patients, called Granzyme K, has been shown to be significantly elevated in patients suffering from chronic organ rejection. We have recently discovered that this enzyme is involved in the earliest stages of human organ rejection by promoting inflammation and immune damage to the transplants blood vessels. We plan to study this protein in mice using a model of organ rejection to determine its suitability as a drug target to decrease chronic cardiac transplant rejection.Furthermore, we suspect this enzyme could serve as a marker for the early development of transplant rejection. As a marker, we suspect that it will help identify those patients who require invasive investigations and treatments for the management of their rejection versus those patients who can be treated with medical therapy alone. This would prevent patients from receiving unnecessary and potentially harmful interventions. Ultimately, we suspect that the study of Granzyme K will increase the survival and quality of life of transplant patients both by serving as an early marker for rejection, and as a drug target. Given Granzyme K's promotion of inflammation in blood vessels, there is potential for it to also be involved in non-transplant heart diseases as well.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367365
Name
Tauh Keerit
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Granzyme K and Cardiac Allograft Vasculopathy: A novel therapeutic target
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Allograft Vasculpathy; Arteriosclerosis; Coronary Artery Disease; Graft Rejection; Granzyme; Inflammation; Protease; Transplantation
Abstract
Chronic rejection is the number one cause of death in heart transplant patients after one year. An inflammatory protein measured in the bloodstream of transplant patients, called Granzyme K, has been shown to be significantly elevated in patients suffering from chronic organ rejection. We have recently discovered that this enzyme is involved in the earliest stages of human organ rejection by promoting inflammation and immune damage to the transplants blood vessels. We plan to study this protein in mice using a model of organ rejection to determine its suitability as a drug target to decrease chronic cardiac transplant rejection.Furthermore, we suspect this enzyme could serve as a marker for the early development of transplant rejection. As a marker, we suspect that it will help identify those patients who require invasive investigations and treatments for the management of their rejection versus those patients who can be treated with medical therapy alone. This would prevent patients from receiving unnecessary and potentially harmful interventions. Ultimately, we suspect that the study of Granzyme K will increase the survival and quality of life of transplant patients both by serving as an early marker for rejection, and as a drug target. Given Granzyme K's promotion of inflammation in blood vessels, there is potential for it to also be involved in non-transplant heart diseases as well.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tauh, Keerit
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~